First Time Loading...

Concert Pharmaceuticals Inc
NASDAQ:CNCE

Watchlist Manager
Concert Pharmaceuticals Inc Logo
Concert Pharmaceuticals Inc
NASDAQ:CNCE
Watchlist
Price: 8.37 USD Market Closed
Updated: May 10, 2024

Concert Pharmaceuticals Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Concert Pharmaceuticals Inc
Income from Continuing Operations Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Concert Pharmaceuticals Inc
NASDAQ:CNCE
Income from Continuing Operations
-$80.1m
CAGR 3-Years
-13%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Income from Continuing Operations
$4.9B
CAGR 3-Years
2%
CAGR 5-Years
-3%
CAGR 10-Years
2%
Gilead Sciences Inc
NASDAQ:GILD
Income from Continuing Operations
$456m
CAGR 3-Years
19%
CAGR 5-Years
-40%
CAGR 10-Years
-21%
Amgen Inc
NASDAQ:AMGN
Income from Continuing Operations
$3.8B
CAGR 3-Years
-19%
CAGR 5-Years
-14%
CAGR 10-Years
-2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Income from Continuing Operations
$3.6B
CAGR 3-Years
10%
CAGR 5-Years
47%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Income from Continuing Operations
$3.9B
CAGR 3-Years
-1%
CAGR 5-Years
10%
CAGR 10-Years
26%

See Also

What is Concert Pharmaceuticals Inc's Income from Continuing Operations?
Income from Continuing Operations
-80.1m USD

Based on the financial report for Dec 31, 2021, Concert Pharmaceuticals Inc's Income from Continuing Operations amounts to -80.1m USD.

What is Concert Pharmaceuticals Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-10%

Over the last year, the Income from Continuing Operations growth was -7%. The average annual Income from Continuing Operations growth rates for Concert Pharmaceuticals Inc have been -13% over the past three years , -10% over the past five years .